secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001104659-26-034951
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin raises up to $104.5M, advances QRX003 regulatory path, reports 2025 net loss $15.8M
--------------------------------------------------------------------------------

- Closed private placement for up to $104.5M ($16.5M at closing, $88M warrant potential).
- FDA grants Fast Track Designation; single Phase 3 study may suffice for NDA; plan to file in 2027.
- Orphan Drug Designations for QRX003 in Netherton Syndrome in US and Europe; Rare Pediatric Disease Designation could yield $150-200M PRV.
- Pediatric Netherton study expanded to 7 children with sustained skin healing, no adverse events; Peeling Skin study to 6 subjects.
- Cash $18.7M at Dec 31, 2025; net loss Q4 $4.3M vs $2.3M YoY; full year $15.8M vs $9.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926034951/0001104659-26-034951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926034951/tm269662d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-034951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer